ScholarIQanswers from OpenAlex & ORCID
Robert B. Livingston
ResearcherPublications, citations & collaboration network
Robert B. Livingston is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Robert B. Livingston have?
ScholarIQindexed works
Robert B. Livingston has 441 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Robert B. Livingston have?
ScholarIQcitation count
Robert B. Livingston has 34,825 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Robert B. Livingston?
ScholarIQh-index
Robert B. Livingston has an h-index of 85 in OpenAlex.
What is the i10-index of Robert B. Livingston?
ScholarIQi10-index
Robert B. Livingston has an i10-index of 241 in OpenAlex.
What is the OpenAlex record for Robert B. Livingston?
ScholarIQopenalex
The OpenAlex for Robert B. Livingston is on the source record.
What are the most-cited papers on Robert B. Livingston?
ScholarIQmost cited works
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton, Robert B. Livingston, David C. Johnson, James R. Rigas, Michael Johnston, Charles Butts, Yvon Cormier, Glenwood Goss, Richard Inculet, Eric Vallières, Willard A. Fry, Drew Bethune, Joseph Ayoub, Keyue Ding, Lesley Seymour, Barbara Graham, Ming‐Sound Tsao, David R. Gandara, Kenneth A. Kesler, Todd L. Demmy, Frances A. Shepherd
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Paul E. Goss, James N. Ingle, Silvana Martino, Nicholas J. Robert, Hyman B. Muss, Martine Piccart, Monica Castiglione, Dongsheng Tu, Lois E. Shepherd, Kathleen I. Pritchard, Robert B. Livingston, Nancy E. Davidson, Larry Norton, Edith A. Perez, Jeffrey S. Abrams, Patrick Therasse, Michael Palmer, Joseph L. Pater
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Marc L. Citron, Donald A. Berry, Constance Cirrincione, Clifford A. Hudis, Eric P. Winer, William J. Gradishar, Nancy E. Davidson, Silvana Martino, Robert B. Livingston, James N. Ingle, Edith A. Perez, John T. Carpenter, David D. Hurd, James F. Holland, Barbara L. Smith, Carolyn I. Sartor, Eleanor H. Leung, Jeffrey S. Abrams, Richard L. Schilsky, Hyman B. Muss, Larry Norton
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S. Albain, Ruth Swann, Valerie W. Rusch, Andrew T. Turrisi, Frances A. Shepherd, Colum J Smith, Yuhchyau Chen, Robert B. Livingston, Richard H. Feins, David R. Gandara, Willard A. Fry, Gail Darling, David H. Johnson, Mark R. Green, Robert C. Miller, Joanne Ley, W. Sause, James D. Cox
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain, William E. Barlow, Steven Shak, Gabriel N. Hortobágyi, Robert B. Livingston, I‐Tien Yeh, Peter M. Ravdin, Roberto Bugarini, Frederick L. Baehner, Nancy E. Davidson, George W. Sledge, Eric P. Winer, Clifford A. Hudis, James N. Ingle, Edith A. Perez, Kathleen I. Pritchard, Lois E. Shepherd, Julie R. Gralow, Carl Yoshizawa, D. Craig Allred, C. Kent Osborne, Daniel F. Hayes